BRIEF published on 11/04/2024 at 11:51, 1 year 10 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 10 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 10 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 10 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 2 years 1 month ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 07/09/2024 at 20:45, 2 years 1 month ago Inside Information / News release on accounts, results Acticor Biotech publishes its 2023 annual results, financial highlights, and financing outlook. Annual General Meeting scheduled for September 13, 2024 Annual General Meeting Financial Highlights 2023 Annual Results ACTICOR BIOTECH Financing Outlook
BRIEF published on 05/15/2024 at 11:20, 2 years 3 months ago Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH Stroke Treatment ACTICOR BIOTECH Glenzocimab ESOC 2024 ACTISAVE Study
PRESS RELEASE published on 05/15/2024 at 11:15, 2 years 3 months ago Inside Information / Other news releases ACTICOR BIOTECH presents main results of phase 2/3 ACTISAVE study on stroke treatment at ESOC 2024, targeting specific subgroups for potential benefits Stroke Treatment ACTICOR BIOTECH ESOC 2024 ACTISAVE Study Patient Subgroups
Published on 09/05/2026 at 04:05, 1 day 4 hours ago Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 1 day 8 hours ago FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 1 day 9 hours ago Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 1 day 9 hours ago Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 1 day 17 hours ago Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Published on 09/06/2026 at 06:00, 2 hours 7 minutes ago CoolFly to Showcase Personal Flight Portfolio and NA80 Flight-Control Technology at IFA Berlin 2026
Published on 09/06/2026 at 05:15, 2 hours 53 minutes ago Experience AI Companion in Everyday Life at Hisense IFA 2026
Published on 09/05/2026 at 22:20, 9 hours 48 minutes ago PITAKA Marks Its Next Chapter in Berlin With "Signals in the Wind," Unveiling New iPhone 18 Accessories
Published on 09/05/2026 at 19:35, 12 hours 33 minutes ago ToolDance Unveils X1 Smart Desktop CNC Mill at IFA 2026
Published on 09/05/2026 at 14:00, 18 hours 8 minutes ago Global investment boom could create USD 200 billion commercial insurance opportunity amid rising accumulation risks, finds Swiss Re Institute
Published on 09/04/2026 at 18:57, 1 day 13 hours ago Disclosure of transactions in own shares from September 1 to September 4, 2026
Published on 09/04/2026 at 17:45, 1 day 14 hours ago Declaration of voting rights at the end of August 2026
Published on 09/04/2026 at 16:00, 1 day 16 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2026
Published on 09/04/2026 at 16:00, 1 day 16 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2026
